Andrew D Simmons
Overview
Explore the profile of Andrew D Simmons including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
2187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abida W, Campbell D, Patnaik A, Bryce A, Shapiro J, Bambury R, et al.
Eur Urol
. 2023 Jun;
84(3):321-330.
PMID: 37277275
Background: Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA1 or BRCA2 (BRCA) or other...
2.
Zboralski D, Osterkamp F, Christensen E, Bredenbeck A, Schumann A, Hoehne A, et al.
Eur J Nucl Med Mol Imaging
. 2023 Apr;
50(9):2621-2635.
PMID: 37086273
Purpose: FAP is a membrane-bound protease under investigation as a pan-cancer target, given its high levels in tumors but limited expression in normal tissues. FAP-2286 is a radiopharmaceutical in clinical...
3.
Loehr A, Hussain A, Patnaik A, Bryce A, Castellano D, Font A, et al.
Eur Urol
. 2022 Oct;
83(3):200-209.
PMID: 36243543
Background: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors are approved in the USA for the treatment of patients with BRCA1 or BRCA2 (BRCA) mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC). BRCA reversion...
4.
Liao M, Beltman J, Giordano H, Harding T, Maloney L, Simmons A, et al.
Clin Pharmacokinet
. 2022 Sep;
61(11):1477-1493.
PMID: 36107395
Rucaparib is an oral small-molecule poly(ADP-ribose) polymerase inhibitor indicated for patients with recurrent ovarian cancer in the maintenance and treatment settings and for patients with metastatic castration-resistant prostate cancer associated...
5.
Robillard L, Liao M, Nguyen M, Harding T, Simmons A, Dusek R
J Immunother
. 2022 Jul;
45(8):335-348.
PMID: 35791438
Lucitanib is a multi-tyrosine kinase inhibitor whose targets are associated with angiogenesis and other key cancer and immune pathways. Its antiangiogenic properties are understood, but lucitanib's immunomodulatory activity is heretofore...
6.
Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al.
Eur J Nucl Med Mol Imaging
. 2022 May;
49(11):3651-3667.
PMID: 35608703
Purpose: Fibroblast activation protein (FAP) is a membrane-bound protease that has limited expression in normal adult tissues but is highly expressed in the tumor microenvironment of many solid cancers. FAP-2286...
7.
Green M, Ma S, Goble S, Giordano H, Maloney L, Simmons A, et al.
Cancer Chemother Pharmacol
. 2022 Apr;
89(5):671-682.
PMID: 35397664
Purpose: To develop a population pharmacokinetics (PPK) model for rucaparib, an oral poly(ADP-ribose) polymerase inhibitor. Methods: The PPK analysis used PK data from patients in Study 1014 (NCT01009190, n = ...
8.
Loehr A, Patnaik A, Campbell D, Shapiro J, Bryce A, McDermott R, et al.
Clin Cancer Res
. 2021 Oct;
27(24):6677-6686.
PMID: 34598946
Purpose: The PARP inhibitor rucaparib is approved in the United States for patients with metastatic castration-resistant prostate cancer (mCRPC) and a deleterious germline and/or somatic or (BRCA) alteration. While sequencing...
9.
Konecny G, Oza A, Tinker A, Oaknin A, Shapira-Frommer R, Ray-Coquard I, et al.
Gynecol Oncol
. 2021 Mar;
161(3):668-675.
PMID: 33752918
Objective: To evaluate correlations between rucaparib exposure and selected efficacy and safety endpoints in patients with recurrent ovarian carcinoma using pooled data from Study 10 and ARIEL2. Methods: Efficacy analyses...
10.
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a or Gene Alteration
Abida W, Patnaik A, Campbell D, Shapiro J, Bryce A, McDermott R, et al.
J Clin Oncol
. 2020 Aug;
38(32):3763-3772.
PMID: 32795228
Purpose: or () alterations are common in men with metastatic castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly(ADP-ribose) polymerase inhibitors. We present results from patients with mCRPC associated...